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Abstract
Background: In the spectrum of molecular alterations found in hepatocellular carcinoma (HCC), somatic mutations
in the WNT/β-catenin pathway and the p53/cell cycle control pathway are among the most frequent ones. It has
been suggested that both mutations occur in a mutually exclusive manner and they are used as molecular classifiers in
HCC classification proposals.
Case presentation: Here, we report the case of a treatment-naïve mixed hepatocellular/cholangiocellular carcinoma
(HCC/CCC) with morphological and genetic intratumor heterogeneity. Within the predominant part of the tumor with
hepatocellular differentiation, a p.D32V mutation in exon 3 of the CTNNB1 gene occurred concomitantly with a TP53
intron 7/exon 8 splice site mutation.
Conclusion: Intratumor heterogeneity challenges the concept of CTNNB1 and TP53 gene mutations being mutually
exclusive molecular classifiers in HCC, which has implications for HCC classification approaches.
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Background
Hepatocellular carcinoma (HCC) is the fifths most com-
mon cancer in men and the second most common cause
for cancer-related death worldwide [1]. HCC mostly
develop on the background of chronic liver diseases
including chronic viral hepatitis due to infection with
hepatitis B virus (HBV), or hepatitis C virus (HCV),
alcohol-induced liver injury, fatty liver disease or expos-
ure to toxic factors such as aflatoxin. The spectrum of
somatic mutations related to liver carcinogenesis has
been identified [2]. With marked geographic variation,
TP53 and CTNNB1 represent two of the most common
driver mutations in the African-Asian countries (TP53)
and in the western world (CTNNB1). Several molecular
classifications of HCC distinguish HCC with alterations
in the p53/cell cycle control pathway from HCCs with
alterations in the WNT/β-catenin pathway, including ac-
tivating mutations of the CTNNB1 oncogene, AXIN1 or
APC [3, 4]. Mutations of TP53 and CTNNB1 are largely
considered to occur in a mutually exclusive manner [5].
Phenotypical and genetic intratumor heterogeneity with
variable mutational status (i.e. wild type among mutated
tumor cell clones) of TP53 and CTNNB1 in different
tumor regions within the same tumor is frequently
found in HCC [6]. Here, we describe a de novo, hepatitis
C-related combined cholangiocellular and hepatocellular
carcinoma with marked intratumor heterogeneity on
three levels: morphology, immunohistochemical marker
profile and mutational status with 3/14 tumor regions of
solely hepatocellular differentiation harboring concomi-
tant mutations of CTNNB1 and TP53.
Case presentation
A liver tumor was detected in a 72 year old male patient
with liver cirrhosis Child-Pugh Stage A, a history of type 2
diabetes and chronic hepatitis C virus infection (HCV,
genotype 1B), initially diagnosed 13 years ago. Liver en-
zymes were slightly elevated with alanine aminotransfer-
ase 89 U/L (reference: 10–50 U/L) and aspartate
aminotransferase 65 U/L (reference: <50 U/L). The 4 cm
tumor was detected by routine sonography and removed
by laparoscopic liver segment resection.
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Morphological analysis, immunohistochemistry and
multiregional, next generation sequencing (NGS) was
applied on representative tumor sections as described
[6]. Table 1 and Fig. 1 illustrate histopathological and
molecular findings in 14 individual tumor areas, which
were grouped into three tumor regions (A, B and C) ac-
cording to their predominant morphological and molecu-
lar characteristics. In summary, a multinodular, combined
hepatocellular/cholangiocellular carcinoma, tumor stage
T1 grade 2–3, was diagnosed. Intratumoral heterogeneous
expression of five liver cell markers (CK7, CK19, glutam-
ine synthetase, p53, β-catenin) was detected including a
double positivity for glutamine synthetase, nuclear β-
catenin and p53 in tumor region A.
Next generation sequencing was performed with a
minimum coverage of 1329 (SD ± 725) reads per ampli-
con of every single tumor area. Sequencing results
yielded a p.D32V (c.363 A > T) mutation and a TP53
ivs8-1 (c.783-1 G > A) splice site mutation in tumor re-
gion A. Comparing mutated allele frequencies, CTNNB1
and TP53 gene copies showed a similar range of both
frequencies in area A1-3 (Fig. 1). All mutated and wild
type tumor areas additionally displayed a SNP of exon 7
(rs17880604). Collectively, morphological and immuno-
histochemical findings together with sequencing results
demonstrated that a tumor subclone with hepatocellular
differentiation had concomitant CTNNB1 and TP53
gene mutations.
To date, after a follow-up time of 12 months, the pa-
tient had a local recurrence of a liver tumor which was
inoperable and therefore treated by transarterial che-
moembolization (TACE).
Conclusion
In this case of a HCV infection -related liver cancer, a
CTNNB1/TP53 double mutation was detected in a tumor
region of hepatocellular differentiation, among TP53 and
CTNNB1 wild type tumor areas. The analysis of mutated
allele frequencies using next generation sequencing tech-
niques corroborates that the double mutation is located in
the same tumor cell population. To our knowledge, this is
the first detailed description of a CTNNB1/TP53 double
mutation in a single liver cancer lesion. TP53 and
CTNNB1 both are molecular classifiers for hepatocellular
carcinoma. For instance, in the transcriptome-analysis
based classification proposal by Boyault et al. [4], six HCC
subgroups are distinguished: two groups are characterized
by TP53 and two independent groups by CTNNB1 alter-
ations. A study by Laurent-Puig et al. [5] on genetic
alterations in hepatocarcinogenesis describes TP53 and
CTNNB1 mutations as mutually exclusive. In agreement,
a study by Tornesello et al. [7] records mutations of the
two driver genes as being mutually exclusive.
CTNNB1 mutations are reported to be associated with
hepatitis C infections [8]. TP53 point mutations fre-
quently are reported to occur specifically at codon 249
after aflatoxin exposition. The frequency and the causal
link between TP53 and CTNNB1 mutations in HCC
have not been systematically investigated. A study by
Ötztürk et al. [9] on HCC cell lines provides evidence
that inactivation of TP53 could cause aberrant nuclear
β-catenin accumulation, suggesting a link between the
two genes. In the presented case study, the CTNNB1
mutation affected the GSK-3β phosphorylation site [10]
which argues for a β-catenin accumulation independent
Table 1 Morphology, immunohistochemistry and mutational status of individual tumor areas
Area A1 A2 A3 B C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
Size in mm2 7.8 5.54 31.3 65 73.2 16.5 34.5 82.2 20.2 18.9 17.4 28.5 1.94 17.5
Morphology Solid + + + + + + + + +
Glandular (cholangiocellular) +
Trabecular + + + + +
Clear cell change + + +
Fatty change +
CK19 >50 % >50 %
IC CK7 70 % SC 50 % 20 % SC 40 % SC SC 50 %
glutamine synthetase + + +
β-catenin nuclear + + +
p53 + + +
Mutation CTNNB1 sanger seq D32 D32 wt wt wt wt wt wt wt wt wt wt wt wt
CTNNB1 deep seq D32 D32 D32a wt wt wt wt wt wt wt wt wt wt wt
TP53 sanger seq IVS8-1 IVS8-1 wt wt wt wt wt wt wt wt wt wt wt wt
TP53 deep seq IVS8-1 IVS8-1 IVS8-1a wt wt wt wt wt wt wt wt wt wt wt
sanger seq sanger sequencing, deep seq deep sequencing (NGS), wt wild type, SC single cells positive
alow frequency (<10 %)
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Fig. 1 Combined HCC/CCC in a 72 year old male patient with history of hepatitis C and diabetes revealing morphological, immunohistochemical and
genetic intratumor heterogeneity. a Gross morphology and slide overview (H&E staining) with annotations of defined tumor areas. b Microscopic
images (40x) of different tumor areas (H&E staining, CK7, glutamine synthetase and β-catenin immunohistochemistry). c p53 and β-catenin nuclear
positivity in consecutive slides of tumor area A2. d Nucleotide exchanges in CTNNB1 and TP53 genes (TP53 depicted as reverse sequence). e Mutated
allele frequencies of double mutated areas A1-3 with number of gene copies analyzed. Reference sequences: NM 1904.1 (CTNNB1) and
NM 001126112.2 (TP53)
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from the TP53 mutation. The detected TP53 mutation
affects a splice site of exon 8. Although splice sites in
TP53 are not typical mutation sites, there is evidence
that TP53 splicing mutations lead to exon dropping
indicating biological relevance [11]. Furthermore, the
nuclear accumulation of the dysfunctional p53 protein
in immunohistochemical analysis found in this case
supports a functional significance of this splice site
mutation. As has been reported, wild type p53 is rap-
idly degraded while mutations lead to nuclear accu-
mulation of the p53 protein [12, 13].
In summary, the molecular, immunohistochemical and
morphological diversity in the presented case indicates a
high level of intratumor heterogeneity and challenges the
concept that TP53 and CTNNB1 are mutually exclu-
sive driver alterations in HCC. Distinct parts of the tumor
reveal multinodularity, and differ with respect to their bio-
marker expression and mutational status, indicative of dis-
tinct tumor subpopulations [14]. This finding illustrates
the challenge to molecularly characterize individual HCC.
Routine pathological analysis is based on testing a small
piece of a tumor, assuming that it represents the whole
tumor. When analyzing distinct pathways of hepatocarci-
nogenesis such as the WNT/β-catenin pathway as a po-
tential therapeutic target in HCC [15], it will be pivotal in
the future to also take into account the level of intratumor
heterogeneity.
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